---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-097603"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:53:19.361927+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SUPN CFO James P. Kelly resigns; Timothy C. Dec appointed as new CFO

## Summary
- James P. Kelly resigns as EVP & CFO effective August 13, 2021 to join another company.
- Timothy C. Dec appointed SVP & CFO effective August 23, 2021; over 35 years experience, most recently CFO of OpGen.
- Dec receives $375,000 annual base salary, 40% target bonus prorated first year, and 85,000 options vesting over 4 years.
- Dec enters Executive Retention Agreement with severance payments and accelerated vesting upon change in control.

## SEC filing metadata
- accession: 0001104659-21-097603
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/0001104659-21-097603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/tm2123591d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-097603
- JSON: https://secwatch.observer/filing/0001104659-21-097603.json
- Plain text: https://secwatch.observer/filing/0001104659-21-097603.txt

## Key facts
- Executive change
  James P. Kelly resigned as Executive Vice-President and Chief Financial Officer at SUPERNUS PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Executive Vice-President and Chief Financial Officer
  source text: On July 23, 2021, James P. Kelly, Executive Vice-President and Chief Financial Officer, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of his resignation from the Company to join another company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/0001104659-21-097603-index.htm
- Executive change
  Timothy C. Dec was appointed as Senior Vice-President and Chief Financial Officer at SUPERNUS PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Senior Vice-President and Chief Financial Officer
  source text: On July 27, 2021, the Company appointed Timothy C. Dec to the position of Senior Vice-President and Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/0001104659-21-097603-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.